Non-steroidal anti-inflammatory drugs (NSAIDs) induced dyspepsia
P Ray-Yee Yap, KL Goh - Current pharmaceutical design, 2015 - ingentaconnect.com
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prescribed group of drugs in
the world. They are used primarily for pain relief in chronic inflammatory joint disease and …
the world. They are used primarily for pain relief in chronic inflammatory joint disease and …
Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19
T Furuta, M Sugimoto, N Shirai - Molecular diagnosis & therapy, 2012 - Springer
The main therapeutic agent for gastroesophageal reflux disease (GERD) is a proton pump
inhibitor (PPI). Plasma levels and the acid inhibitory effect of PPIs depend on the activity of …
inhibitor (PPI). Plasma levels and the acid inhibitory effect of PPIs depend on the activity of …
Rabeprazole 10 mg qds decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg bd or 40 mg om, overcoming CYP 2 C 19 genotype
M Sugimoto, N Shirai, M Nishino… - Alimentary …, 2012 - Wiley Online Library
Background Standard dosing (ie once daily) of proton pump inhibitors (PPI s) cannot inhibit
acid secretion for a full 24 h. Better therapeutic regimens using PPI s are required to sustain …
acid secretion for a full 24 h. Better therapeutic regimens using PPI s are required to sustain …
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese
M Sugimoto, N Shirai, M Nishino, C Kodaira… - European journal of …, 2014 - Springer
Introduction The aim of therapeutic regimens using proton pump inhibitors (PPIs) in patients
with acid-related diseases is to potently inhibit acid secretion for the full 24 h. However …
with acid-related diseases is to potently inhibit acid secretion for the full 24 h. However …
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low‐dose aspirin
R Iwakiri, K Higuchi, M Kato, M Fujishiro… - Alimentary …, 2014 - Wiley Online Library
Background Few studies have evaluated the effects of rabeprazole on low‐dose aspirin
(LDA)‐induced gastroduodenal injuries. Aim To conduct a randomised, double‐blind, triple …
(LDA)‐induced gastroduodenal injuries. Aim To conduct a randomised, double‐blind, triple …
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype
T Uotani, M Sugimoto, M Nishino, C Kodaira… - Clinical …, 2012 - Elsevier
BACKGROUND & AIMS: Low doses of aspirin can injure the gastric mucosa. It is not clear
whether other drugs such as the antiplatelet agent clopidogrel also cause gastric mucosal …
whether other drugs such as the antiplatelet agent clopidogrel also cause gastric mucosal …
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective …
T Sanuki, T Fujita, H Kutsumi, T Hayakumo… - Journal of …, 2012 - Springer
Background Patients using low-dose aspirin (LDA) have an increased risk of
gastroduodenal mucosal lesions and upper gastrointestinal symptoms. We aimed to clarify …
gastroduodenal mucosal lesions and upper gastrointestinal symptoms. We aimed to clarify …
Acid-NSAID/aspirin interaction in peptic ulcer disease
The presence of gastric acid plays a critical role in the mechanisms of NSAIDs/aspirin-
associated gastric and duodenal mucosal injury and ulceration. The role of gastric acid and …
associated gastric and duodenal mucosal injury and ulceration. The role of gastric acid and …
[HTML][HTML] Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury
K Iijima, T Shimosegawa - World Journal of Gastroenterology: WJG, 2015 - ncbi.nlm.nih.gov
Aspirin, even at low doses, has been known to cause upper gastro-intestinal complications,
such as gastroduodenal ulcers, despite the definite benefits from its antithrombotic effects …
such as gastroduodenal ulcers, despite the definite benefits from its antithrombotic effects …
[HTML][HTML] Proton pump inhibitor therapy before and after endoscopic submucosal dissection: a review
M Sugimoto, JS Jang, Y Yoshizawa, S Osawa… - Diagnostic and …, 2012 - hindawi.com
Endoscopic submucosal dissection (ESD) is a novel endoscopic procedure first developed
in the 1990s which enables en bloc resection of gastric neoplastic lesions that are difficult to …
in the 1990s which enables en bloc resection of gastric neoplastic lesions that are difficult to …